Безопасность длительного применения диеногеста (Визанна) при эндометриозе

To explore the efficiency, safety and tolerability of dienogest for 12 months of treatment of various forms of endometriosis, conducted a study involving 20 patients aged 18 to 45 years (mean age 20.25 ± 3.8 years). All patients suffered surgical treatment of endometriosis varying degrees of distribution. Dienogest treatment was started on day 1 of the first menstrual period after the operation. All patients performed ultrasonography of the pelvic organs. Assess the degree of severity of pain on a visual analog scale. It is also determined by the level of estradiol on day 2-3 of the menstrual cycle before treatment and at 3, 6, 12 months against the backdrop of dienogest therapy. We studied the thrombogenic potential of the blood and blood biochemical parameters in the same periods of time. The study found that Visanna generally well tolerated and is associated with lower incidence of undesirable manifestations.